Memorial Sloan Kettering Cancer Center has patented eponemycin analogues acting as proteasome inhibitors and thus potentially useful for the treatment of cancer.
Researchers from Guangzhou Medical University (GMU) described the discovery of a novel proteasome inhibitor NIC-0102, being developed as an anti-inflammatory therapeutic candidate.
An international collaborative study has identified several novel derivatives of anticancer proteasome inhibitors (PIs) that had potential as antimalarials, the authors reported in the September 28, 2021, online edition of Proceedings of the National Academy of Sciences.
HONG KONG – South Korean biotech company Qurient Co. Ltd. has inked a joint venture (JV) foundation deal involving German companies Max Planck Society (MPG), of Munich, and Lead Discovery Center GmbH (LDC) in Dortmund, as well as the 1988 Nobel laureate and biochemist Robert Huber.
